Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases

Lopez, Anthony; Billioud, Vincent; Peyrin-Biroulet, Carina; Peyrin–Biroulet, Laurent

doi:10.1097/mib.0b013e31828132cb

Cited by 149 publications

(102 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also inferred that the both the polymorphism may have synergistic effect on the susceptibility and may work in tandem to influence the etiology of IBD in Saudi population. The outcome of present study will not only help in the prognosis of IBD in Saudi population but also provide guideline for the treatment with anti-TNF therapy as individuals with different genotypes of TNF-α (-308G/A) respond differently to anti-TNF-α treatment [136,137]. However, further studies are required involving other ethnic populations to strengthen these findings.…”

Section: Discussionmentioning

confidence: 96%

Inflammatory Bowel Disease: The Association of Inflammatory Cytokine Gene Polymorphisms

Al-Robayan¹,

Arfin²,

Meghaiseeb³

et al. 2016

New Insights Into Inflammatory Bowel Disease

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Inflammatory Bowel Disease: The Association of Inflammatory Cytokine Gene Polymorphisms

Al-Robayan¹,

Arfin²,

Meghaiseeb³

et al. 2016

New Insights Into Inflammatory Bowel Disease

View full text Add to dashboard Cite

show abstract

“…Disease activity should also be accessed using an infl ammatory marker [fecal calprotectin usually being more accurate than CRP, especially in ulcerative colitis (UC)] [42] and endoscopy. In addition, non-adherence to medications may occur in up to 29% in IBD patients on anti-TNFs [43].…”

Section: Management Of Lor To Anti-tnfs Guided By Ifx and Ati Levelsmentioning

confidence: 99%

Therapeutic Drug Monitoring in Inflammatory Bowel Disease

2017

View full text Add to dashboard Cite

Tumor necrosis factor (TNF)-α inhibitors and thiopurines are among the most important classes of medications utilized in the clinical management of Crohn's disease and ulcerative colitis. A signifi cant proportion of patients loses response to these agents or develops adverse eff ects during the course of the treatment. Monitoring of drug levels and anti-drug antibodies (for TNF-α inhibitors) and metabolite levels (for thiopurines) can provide valuable insight into the possible etiology of unfavorable outcomes and allow for an appropriate management strategy for these patients. Th is review summarizes the current knowledge on the clinical implications of therapeutic drug monitoring in infl ammatory bowel disease patients treated with TNF-α inhibitors and thiopurines.

show abstract

“…In the studies performed to date, up to 40% of patients with symptoms suggestive of exacerbation do not present active inflammation. We should examine the patient's treatment adherence, estimating that up to 17.4% of patients do not comply with the prescribed biologic treatment [79]. Once these 2 clinical conditions have been ruled out, measuring the levels can more effectively guide our treatment.…”

Section: Use In Clinical Practicementioning

confidence: 99%

Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?

Martín-Arranz¹

2016

GHOA

View full text Add to dashboard Cite

Despite the efficacy demonstrated by anti-TNF drugs in treating inflammatory bowel disease, there is a significant percentage of patients for whom the drugs fail or the response to the drugs is lost. The limitations in managing these patients and the increase in costs necessitate an individualised strategy to optimise their clinical management. Recent studies have noted the relationship between the clinical outcome and therapeutic adjustments based on monitoring anti-TNF levels and the presence of antibodies, taking into account other factors such as the type of disease and its severity. This study reviews the available information and proposes a clinical management algorithm to achieve a more efficient result.

show abstract

Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases

Abstract: More than three-quarters of patients with IBD adhere to biologics. Predictors of nonadherence include female gender, smoking, constraints related to treatment, anxiety, and moodiness. These data could be used to develop intervention studies aimed at improving adherence to biologics in IBD.

Cited by 149 publications

References 35 publications

Inflammatory Bowel Disease: The Association of Inflammatory Cytokine Gene Polymorphisms

Inflammatory Bowel Disease: The Association of Inflammatory Cytokine Gene Polymorphisms

Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?

Contact Info

Product

Resources

About